Pretax income is the income that a company earns before paying income taxes. Foghorn Therapeutics's pretax income for the
three
months ended in Mar. 2024 was $-25.02 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Mar. 2024 was $-89.29 Mil.
Foghorn Therapeutics's pretax margin was -495.37%.
During the past 6 years, Foghorn Therapeutics's highest Pretax Margin was -263.42%. The lowest was -16000.00%. And the median was -4123.93%.
Foghorn Therapeutics Pre-Tax Income Historical Data
The historical data trend for Foghorn Therapeutics's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Foghorn Therapeutics's Pre-Tax Income
For the Biotechnology subindustry, Foghorn Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Foghorn Therapeutics's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Foghorn Therapeutics's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Foghorn Therapeutics's Pre-Tax Income falls into.
Foghorn Therapeutics Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
Foghorn Therapeutics's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as
Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-89.29 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Foghorn Therapeutics (NAS:FHTX) Pre-Tax Income Explanation
Foghorn Therapeutics's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as
During the past 6 years, Foghorn Therapeutics's highest Pretax Margin was -263.42%. The lowest was -16000.00%. And the median was -4123.93%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Foghorn Therapeutics Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Foghorn Therapeutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Foghorn Therapeutics (Foghorn Therapeutics) Business Description
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FHTX has been successfully added to your 